British Society for Rheumatology > Knowledge > Excellence > Guidelines

Guidelines

Knowledge * Excellence * Guidelines

Guidelines are key to modern rheumatological healthcare.

NICE accreditation 

NICE has accredited the process used by British Society for Rheumatology to produce its clinical guidance. Accreditation is valid for five years from February 2013. 


For full details on our accreditation visit nice.org.uk/accreditation

View the current Protocol we follow when developing our guidelines.

We neither seek nor accept industry funding for any of our guidelines. They are supported through our general finances.  

Creating our guidelines is a major voluntary endeavour by members, patients and practitioners from primary care and other specialities. We are grateful to everyone for their strenuous efforts in producing them.

Current guidelines:

Biological DMARD safety

Guideline for the safe prescribing of biologics in adults with inflammatory arthritis

Executive summary >

Full guideline >

2018 NICE accredited

Lupus

Guideline for the management of adults with Systemic Lupus Erythematosus

Executive summary >

Full guideline >

Audit tool >

Lupus podcast >

2017 NICE Accredited

Due for revision in 2020

Sjögren’s Syndrome

Guideline for the management of adults with Primary Sjögren’s Syndrome

Executive summary >

Full guideline >

Audit tool >

Sjogren's podcast >

2017 NICE Accredited

Due for revision in 2020

Gout

Guideline for the management of gout

Executive summary >

Full guideline >

Audit tool >

Gout podcast >

2017 NICE Accredited

Due for revision in 2020

DMARDs

Guideline for the prescription and monitoring of non-biologic Disease-Modifying Anti-Rheumatic Drugs

Executive summary >

Full guideline >

Audit tool >

DMARDs podcast >

2017 NICE Accredited

Due for revision in 2020

Axial spondyloarthritis

Guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics

Executive summary >

Full guideline >

Audit tool >

Axial Spondyloarthritis podcast

2016 NICE Accredited

Due for revision in 2019

Systemic sclerosis

Guideline for the treatment of systemic sclerosis

Executive summary >

Full guideline >

Audit content on page 10 of Full guideline

Systematic sclerosis podcast

2016 NICE Accredited

Due for revision in 2019

Pregnancy and breastfeeding - part 1

Guideline on prescribing drugs in pregnancy and breastfeeding Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids

Executive summary >

Full guideline >

Audit tool >

Pregnancy podcast

2016 NICE Accredited

Due for revision in 2019

Pregnancy and breastfeeding - part 2

Guideline on prescribing drugs in pregnancy and breastfeeding Part 2: analgesics and drugs used in rheumatology practice

Executive summary >

Full guideline >

Audit tool >

Pregnancy podcast

2016 NICE Accredited

Due for revision in 2019

PsA with biologics

Guideline for the treatment of psoriatic arthritis with biologics

See revision statement below

Executive summary >

Full guideline >

PsA guidelines revision statement >

2013 NICE Accredited

Due for revision in 2017

Hot swollen joint

Guideline for management of hot swollen joint in adults

The guideline for the management of the hot swollen joint was first published in 2006. Although there is not enough data to constitute a change in the guideline, there is sufficient new information to warrant an update within the next two years. Read the accompanying statement for more detail. March 2017.

Executive summary >

Full guideline >

Hot Joint guideline update >

Renewed and accepted unchanged in 2012. Reviewed again in 2017. An update of the guideline will be due within the next two years.

Due for revision in 2019

Polymyalgia rheumatica

Guideline for the management of polymyalgia rheumatica

SAGWG decided that the 2009 guideline, originally due for review 2015, remains current. It is substantially the same as the new 2015 EULAR/ACR guideline: Recommendations for the Management of Polymyalgia Rheumatica.

Executive summary >

Full guideline >

Due for revision in 2018

ANCA associated vasculitis

Guideline for the management of adults with ANCA associated vasculitis

Executive summary >

Full guideline and suggestions for audit >

Due for revision in 2018

 

Guidelines under revision:

Giant cell arteritis

Management of giant cell arteritis

Executive summary >

Due for publication in 2019

PsA with biologics

The Treatment of PsA with biologics

Executive summary >

Due for publication in 2019

ANCA associated vasculitis

The management of adults with ANCA associated vasculitis

Executive summary >

Due for publication in 2019

 

New guidelines in development:

Adults patients with idiopathic inflammatory myopathy

Management of adult patients with idiopathic inflammatory myopathy (myositis)

Paediatric patients with idiopathic inflammatory myopathy

Management of paediatric patients with idiopathic inflammatory myopathy (myositis)

Persistent pain

Persistent pain in inflammatory arthritis

Latest Tweet

@RheumatologyUK

New to #Twitter or want to meet fellow #tweeters? Join the official #Rheum2017 tweetup, BSR stand, 08:30, 25 Apr, exhibition hall

Contact us

British Society for Rheumatology
Bride House, 18-20 Bride Lane,
London EC4Y 8EE
T: +44 (0) 20 7842 0900
E: bsr@rheumatology.org.uk
Company No: 3470316
Charity No: 1067124
VAT No: 404 5637 66

Join us

We are the UK's leading specialist medical society for rheumatology and musculoskeletal professionals, and we welcome applications from all health professionals in these fields.